RAPT

RAPT Therapeutics, Inc. (NASDAQ:RAPT) is a clinical-stage immunology-based biopharmaceutical company founded in 2015 and headquartered in South San Francisco, California. Originally incorporated as FLX Bio, Inc., the company changed its name to RAPT Therapeutics in May 2019 and went public in October 2019. The company focuses on discovering, developing, and commercializing oral small molecule therapies targeting unmet medical needs in oncology and inflammatory diseases, with particular expertise in developing drugs that modulate immune cell migration and function.